Neogenomics Laboratories

NeoGenomics News

12/01/2021

Test Updates


Flow Cytometry


Effective Monday, December 6th, the following MRD Flow panels will be updated with additional antibodies for enhanced MRD detection. These panels will be run with 12-color flow cytometry technique in one single tube for speed, efficiency, and thoroughness.

  • B-ALL MRD Flow Panel – Markers will include: CD66c/CD123, CD304/CD73, 7AAD, CD34, CD13/CD33, CD10, CD19, CD20, CD45, CD38, CD58, CD22

CPT codes* will be updated to 88184x1, 88185x11 plus 88188x1 for both panels. Updated Flow User's Guide will be available for download on NeoLINK on December 6.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Molecular


NeoTYPE® Lung Tumor Profile

Detection of ALK, RET, and ROS1 mutations (SNVs and indels) will be added to the NeoTYPE® Lung Tumor Profile beginning with samples received Monday, December 6th. Understanding mutation status of these genes is important for therapeutic management of patients with non-small cell lung cancer.

  • No changes to level of service, CPT Codes, or TAT

 


Date change for online orders BRAF to MLH1 Promoter Methylation reflex: Please note that the option to select MLH1 Promoter Methylation as a reflex test after negative BRAF Mutation Analysis will become available online orders in late January rather than December 6th as previously announced. We will notify you of the effective date closer to that time. This reflex remains available for order on paper requisitions. 



IHC


Beginning with samples processed Friday, November 19th, the BRAF V600E IHC test now uses the IHC600 clone instead of the VE1 clone. This is due to the VE1 clone being on backorder by the manufacturer. The newly established IHC600 clone was correlated to molecular BRAF Mutation Analysis results ran on a variety of tumor types including melanoma, hairy cell leukemia, and colorectal cancer, providing confidence in performance.

  • The VE1 clone will continue to be listed on the BRAF External QC Report, as we work to get this information updated within the reporting system
  • No changes to level of service, CPT Codes, or TAT